



Ther 2016; 167: 132–145.

**10.** Camin RM, et al. Acute kidney injury secondary to combination of renin-angiotensin systém inhibitors, diuretics and NSAIDs: „the triple whammy“. *Nefrologia* 2015; 35: 197–206.

**11.** Dreischulte T, et al. Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin-angiotensin systém inhibitors in the community increases the risk of acute kidney injury. *Kidney Int* 2015; 88: 396–403.

**12.** Zager RA. Pathogenetic mechanisms in nephrotoxic acute renal failure. *Semin Nephrol* 1997; 17: 3–14.

**13.** Markowitz GS, et al. Drug-induced renal failure: a focus on tubulointerstitial disease. *Clin Chim Acta* 2005; 351: 31–47.

**14.** Naughton CA. Drug-induced nephrotoxicity. *Am Fam Physician* 2008; 78: 743–750.

**15.** Rossert J. Drug-induced acute interstitial nephritis. *Kidney Int.* 2001; 60: 804–817.

**16.** Moledina DG, Perazella MA. Drug-induced acute interstitial nephritis. *Clin AJ Am Soc Nephrol* 2017; 12: 2046–2049.

**17.** Douros A, et al. Drug-induced kidney injury: a large case series from the Berlin Case-Control Surveillance Study. *Clin Nephrol* 2018; 89: 18–26.

**18.** Perazella MA. Pharmacology behind common drug nephrotoxicities. *Clin J Am Soc Nephrol* 2018; 13: 1897–1908.

**19.** Shahrabaf FG, Assadi F. Drug-induced renal disorders. *J Renal Inj Prev* 2015; 4: 57–60.

**20.** Piereson-Marchandise M, et al. The drugs that mostly frequently induce acute kidney injury: a case-noncase study of a pharmacovigilance database. *Br J Clin Pharmacol* 2017; 83: 1341–1349.

**21.** Zhang X, et al. Non-steroidal anti-inflammatory drug Induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. *BMC Nephrol* 2017; 18(1): 256. doi: 10.1186/s12882-017-0673-8

**22.** Gayat E, et al. Impact of angiotensin-converting enzyme inhibitors or receptor blockers in post-ICU discharge outcome in patients with acute kidney injury. *Intensive Care Med* 2018; 44: 598–605.

**23.** Saly DL, Perazella MA. Harnessing basic and clinic tools to evaluate SGLT2 inhibitor nephrotoxicity. *Am J Physiol Renal Physiol* 2017; 313: F951–F954. doi: 10.1152/ajprenal.00250.2017.

**24.** FDA Adverse Event Reporting System (FAERS) Public Dashboard [cit. 2020-03-23]. Dostupné z: <https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard>.

**25.** Perlman A, et al. Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: analysis of the FDA adverse event report systém database. *Nutr metqab Cardiovasc Dis* 2017; 27: 1108–1113.

**26.** FDA Drug Safety Communitation 6–14–2016: FDA strenghtens kidney warning for diabetes Medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XE). Dostupné z: <https://www.fda.gov/media/98683/download>.

**27.** Perlman A, et al. Clinical spectrum and mechanism of acute kidney injury in patients with DM on SGLT-2 inhibitors. *IMAJ* 2018; 20: 513–515.

**28.** EMA: EPAR-Product Information Invokana (kanagliflozin), Muntipharma 2020/2. Dostupné z: <https://www.ema.europa.eu/en/medicines/human/EPAR/invokana#product-information-section>

**29.** Kubát K, et al. 23 případů metforminem indukované metabolické laktátové acidózy. *Klin Biochem Metab* 2017; 15: 77–85.

**30.** Svoboda L. Poškození ledvin kontrastní látkou. *Med. Pro Praxi* 2007; 4: 410–415.

**31.** SPC ČR: Siofor (metformin), Berlin-Chemie, 2020/7. Dostupné z: <http://www.sukl.cz/modules/medication/search.php>